Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.70 +6.7%	$32.18	$23.42 ▼ $62.58	$2.24B	0.73	650,331 shs	152,707 shs
ALKS Alkermes	$29.89 +1.7%	$30.16	$22.90 ▼ $36.45	$4.90B	0.44	1.74 million shs	264,591 shs
AXSM Axsome Therapeutics	$114.56 +5.7%	$106.61	$72.21 ▼ $139.13	$5.60B	0.46	665,624 shs	125,332 shs
BPMC Blueprint Medicines	$128.48 +0.1%	$115.15	$73.04 ▼ $128.78	$8.30B	0.89	1.34 million shs	1.05 million shs
GMAB Genmab A/S	$21.52 +1.3%	$21.01	$17.24 ▼ $28.56	$13.78B	0.94	1.24 million shs	242,952 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+3.04%	+5.56%	+5.68%	+38.05%	-11.92%
ALKS Alkermes	+0.51%	+1.35%	-7.35%	+1.98%	+20.56%
AXSM Axsome Therapeutics	+0.85%	+5.28%	-3.13%	+6.63%	+29.65%
BPMC Blueprint Medicines	0.00%	+0.05%	+0.43%	+56.49%	+10.39%
GMAB Genmab A/S	+3.56%	+2.46%	-4.28%	+12.85%	-16.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.0693 of 5 stars	3.4	1.0	4.3	1.8	0.8	1.9
ALKS Alkermes	4.9334 of 5 stars	4.4	3.0	4.2	3.5	2.5	1.9
AXSM Axsome Therapeutics	4.7402 of 5 stars	4.5	1.0	4.5	2.4	4.2	0.6
BPMC Blueprint Medicines	1.5056 of 5 stars	2.1	4.0	0.0	2.0	0.8	0.6
GMAB Genmab A/S	4.0127 of 5 stars	3.3	5.0	0.0	2.8	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.71	Moderate Buy	$58.60	51.43% Upside
ALKS Alkermes	2.83	Moderate Buy	$40.00	33.84% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	50.44% Upside
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.18% Downside
GMAB Genmab A/S	2.67	Moderate Buy	$37.80	75.67% Upside

Current Analyst Ratings Breakdown

Latest ALKS, BPMC, GMAB, AGIO, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.41	N/A	N/A	$27.02 per share	1.43
ALKS Alkermes	$1.56B	3.16	$2.71 per share	11.02	$9.05 per share	3.30
AXSM Axsome Therapeutics	$385.69M	14.62	N/A	N/A	$1.18 per share	97.08
BPMC Blueprint Medicines	$508.82M	16.31	N/A	N/A	$4.70 per share	27.34
GMAB Genmab A/S	$3.12B	4.42	$1.59 per share	13.53	$8.04 per share	2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	3.44	N/A	N/A	1,798.26%	-2.75%	-2.52%	7/30/2025 (Estimated)
ALKS Alkermes	$367.07M	$2.09	14.23	21.82	1.82	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	40.62	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.66	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.76	12.21	12.09	6.69	35.11%	18.08%	14.52%	8/14/2025 (Estimated)

Latest ALKS, BPMC, GMAB, AGIO, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	18.50	17.93
ALKS Alkermes	N/A	3.33	2.92
AXSM Axsome Therapeutics	3.48	2.03	1.96
BPMC Blueprint Medicines	1.01	2.80	2.75
GMAB Genmab A/S	N/A	5.34	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ALKS Alkermes	95.21%
AXSM Axsome Therapeutics	81.49%
BPMC Blueprint Medicines	N/A
GMAB Genmab A/S	7.07%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
ALKS Alkermes	4.40%
AXSM Axsome Therapeutics	22.40%
BPMC Blueprint Medicines	4.21%
GMAB Genmab A/S	1.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	55.06 million	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.21 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.35 million	Optionable

ALKS, BPMC, GMAB, AGIO, and AXSM Headlines

Recent News About These Companies

China Universal Asset Management Co. Ltd. Has $905,000 Stock Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

5 hours ago | marketbeat.com

14,361 Shares in Genmab A/S Sponsored ADR (NASDAQ:GMAB) Acquired by Callan Capital LLC

July 9 at 5:36 AM | marketbeat.com

Truist Financial Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

July 9 at 4:17 AM | americanbankingnews.com

Genmab A/S (NASDAQ:GMAB) Stock Price Expected to Rise, Truist Financial Analyst Says

July 8 at 12:28 PM | marketbeat.com

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Analysts

July 8 at 2:11 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

July 6 at 3:28 AM | marketbeat.com

Genmab Announces Changes to its Executive Committee

July 1, 2025 | globenewswire.com

Completion of Share Buy-back Program

June 30, 2025 | globenewswire.com

Genmab A/S (GMAB) Latest Stock News & Headlines - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Oppenheimer Asset Management Inc. Purchases 42,361 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

June 25, 2025 | marketbeat.com

Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume - Here's Why

June 24, 2025 | marketbeat.com

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

June 23, 2025 | seekingalpha.com

Transactions in Connection with Share Buy-back Program

June 23, 2025 | globenewswire.com

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Acquired by QRG Capital Management Inc.

June 20, 2025 | marketbeat.com

GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

June 19, 2025 | marketbeat.com

Capital Increase in Genmab as a Result of Employee Warrant Exercise

June 17, 2025 | globenewswire.com

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

June 17, 2025 | globenewswire.com

Transactions in Connection with Share Buy-back Program

June 16, 2025 | globenewswire.com

Park Avenue Securities LLC Takes Position in Genmab A/S (NASDAQ:GMAB)

June 16, 2025 | marketbeat.com

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

June 15, 2025 | businesswire.com $https://www.businesswire.com/news/home/20250613776948/en/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-rr-diffuse-large-b-cell-lymphoma-dlbcl-eligible-for-autologous-stem-cell-transplantation-asct/$

June 15, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/15/3099409/0/en/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-el.html$

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
By Gabriel Osorio-Mazilli | June 16, 2025
View China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
Tariff Talks Advance, What Taiwan Semiconductor Can Deliver
By Gabriel Osorio-Mazilli | June 16, 2025
View Tariff Talks Advance, What Taiwan Semiconductor Can Deliver

ALKS, BPMC, GMAB, AGIO, and AXSM Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.70 +2.42 (+6.66%)

As of 11:01 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alkermes NASDAQ:ALKS

$29.89 +0.51 (+1.73%)

As of 11:01 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Axsome Therapeutics NASDAQ:AXSM

$114.56 +6.15 (+5.67%)

As of 11:01 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Blueprint Medicines NASDAQ:BPMC

$128.48 +0.08 (+0.06%)

As of 11:01 AM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Genmab A/S NASDAQ:GMAB

$21.52 +0.27 (+1.26%)

As of 11:01 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time